Volume 2.30 | Aug 19

Prostate Cell News 2.30, August 19, 2011
     In this issue: Science News | Current Publications | Industry News | Policy News | Events
Cell Therapy News on Facebook  Prostate Cell News on Twitter
TOP STORY
Relationship between Two Mutated Genes Can Dictate Prostate Cancer Outcome, Aid Treatment Decisions
Scientists have taken a major step by identifying a new prostate tumor suppressor gene called PHLPP1 and showing that it acts in concert with PTEN, a well-studied tumor suppressor that is mutated in roughly half of prostate cancer patients. [Press release from Cold Spring Harbor Laboratory discussing online prepublication in Cancer Cell]

ON140_AldefluorOptimized_645x110
CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

Identification of PHLPP1 as a Tumor Suppressor Reveals the Role of Feedback Activation in PTEN-Mutant Prostate Cancer Progression
Researchers show that Phlpp1-loss causes neoplasia and, on partial Pten-loss, carcinoma in mouse prostate. [Cancer Cell]

A Cullin3-KLHL20 Ubiquitin Ligase-Dependent Pathway Targets PML to Potentiate HIF-1 Signaling and Prostate Cancer Progression
Researchers show that KLHL20, a Cullin3 substrate adaptor induced by hypoxia-inducible factor 1 (HIF-1), coordinates with the actions of CDK1/2 and Pin1 to mediate hypoxia-induced promyelocytic leukemia (PML) proteasomal degradation. [Cancer Cell]

Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis
The main objective of the present study was to identify microRNA genes that regulate metastatic prostate cancer. [Clin Cancer Res]

ADAM17 Regulates Prostate Cancer Cell Proliferation through Mediating Cell Cycle Progression by EGFR/PI3K/AKT Pathway
In the present study, researchers evaluated the effects of a disintegrin and metalloprotease 17 (ADAM17) on the proliferation and on the cell cycle distribution of human prostate cancer cells. [Mol Cell Biochem]

Dietary Vitamin D (VD) and Vitamin D Receptor (VDR) Level Modulate Epithelial Cell Proliferation and Apoptosis in the Prostate
Researchers tested whether low VD status or VDR deletion influences prostate epithelial cell biology using intact mice, castrated mice, or castrated mice treated with testosterone propionate. [Cancer Prev Res]

Galiellalactone Inhibits Stem Cell-Like Aldehyde Dehydrogenase-Positive Prostate Cancer Cells
In this study researchers aimed to investigate the effect of galiellalactone on prostate cancer stem cell-like cells. [PLoS One]

Genetic Variants in the LEPR, CRY1, RNASEL, IL4, and ARVCF Genes Are Prognostic Markers of Prostate Cancer-Specific Mortality
The purpose of this study was to test whether variation in selected candidate genes in biological pathways of interest for prostate cancer progression could help distinguish patients at higher risk for fatal prostate cancer. [Cancer Epidemiol Biomarkers Prev]

The Interleukin 6 Receptor is a Direct Transcriptional Target of E2F3 in Prostate Tumor Derived Cells
The goal of this study was to identify direct transcriptional targets of E2F3 in prostate tumor derived cells. [Prostate]

Tasquinimod Prevents the Angiogenic Rebound Induced by Fractionated Radiation Resulting in an Enhanced Therapeutic Response of Prostate Cancer Xenografts
Human endothelial and prostate cancer cells in culture and human prostate cancer xenografts growing in castrated male nude mice were evaluated for their response to radiation alone and in combination with tasquinimod. [Prostate]

Expression of LDL-A Module of Relaxin Receptor in Prostate Cancer Cells Inhibits Tumorigenesis
In this study, researchers investigated the effect of low density lipoprotein A (LDL-A) overexpression on prostate cancer cells. [Int J Oncol]

CLINICAL RESEARCH

Dual EGFR/HER2 Inhibition Sensitizes Prostate Cancer Cells to Androgen Withdrawal by Suppressing ErbB3
The overall goal of this study is to determine whether dual inhibition of the receptor tyrosine kinases epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) would prolong the effectiveness of androgen withdrawal therapy in prostate cancer. [Clin Cancer Res]

Low Testosterone Bioavailability is Related to Prostate Cancer Diagnoses in Patients Submitted to Prostate Biopsy
The aim of this study was to determine the relationship between hormone levels and the diagnosis of prostate cancer. [World J Urol]

INDUSTRY NEWS

YCR Invests £2.15 Million in York Stem Cell Research – Yorkshire Cancer Research (YCR) has Awarded £2.15 Million to the University of York to Further Its Internationally Award-Winning Progress into Prostate Cancer Stem Cell Research
The five year funding programme will allow the YCR Cancer Research Unit in the Department of Biology to explore the exact molecular properties that allow prostate cancer stem cells – widely regarded as the ‘root’ cause of all prostate cancers in men – to ultimately survive, spread and resist treatment. [The University of York Press Release]

BIDMC Scientists Receive $2 Million in Challenge Awards from Prostate Cancer Foundation – Researchers Will Pursue New Treatments for Patients with Advanced Prostate Cancer
Researchers have been awarded Challenge Awards of $1 million each from the Prostate Cancer Foundation to lead two cross-disciplinary teams of investigators in their pursuit of new treatments for patients with advanced prostate cancer. [Beth Israel Deaconess Medical Center (BIDMC) Press Release]

CI Awarded $1.86 Million Stem Cell Research Training Grant
California State University Channel Islands (CI) recently won a $1.86 million grant from the California Institute for Regenerative Medicine to help prepare graduate students for careers in stem cell research. [California State University Channel Islands Press Release]

La Jolla Institute Opens Major RNA Interference Center for Identifying Genetic Triggers of Disease
A major center that will propel scientific efforts to pinpoint the specific genes involved in causing immune diseases, cancer and other diseases was opened at the La Jolla Institute for Allergy & Immunology. [La Jolla Institute for Allergy & Immunology Press Release]

POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

EVENTS

NEW International Society for Cell Therapy North American Regional Meeting 
September 14-16, 2011 
Charlottesville, United States 

NEW The Australasian Society of Stem Cell Research 4th Annual Conference 
October 23-25, 2011 
Leura, Australia  

NEW Stem Cells in Drug Discovery and Development 
November 2-3, 2011 
La Jolla, United States 

JOB OPPORTUNITIES

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Scientist (iPSC) (STEMCELL Technologies)

Contract Assay Service Technologist (STEMCELL Technologies)

Research and Development Technologist (STEMCELL Technologies)

Postdoctoral Position – Endocrinology of Prostate Cancer (Baylor College of Medicine)

Prostate Cancer Scientist (McGill University Health Centre) 

Research Associate – Development (Precision Therapeutics, Inc.) 

Postdoctoral Position – Stem Cells and Immunology (University of Connecticut)  

Postdoctoral Fellow in Prostate Cancer Research (University of Texas Southwestern Medical Center)


Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.


Jobs are categorized regionally: United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Prostate Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Prostate Cell News: Archives | Events | Contact Us